Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.

@article{Duncan2017PolymerTA,
  title={Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.},
  author={Robert B. Duncan},
  journal={Journal of drug targeting},
  year={2017},
  volume={25 9-10},
  pages={
          759-780
        }
}
Despite the relatively small early investment, first generation 'polymer therapeutics' have been remarkably successful with more than 25 products licenced for human use as polymeric drugs, sequestrants, conjugates, and as an imaging agent. Many exhibit both clinical and commercial success with new concepts already in clinical trials. Nevertheless after four decades of evolution, this field is arriving at an important crossroads. Over the last decade, the landscape has changed rapidly. There are… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 161 REFERENCES

Overcoming cellular barriers for RNA therapeutics

  • Nature Biotechnology
  • 2017
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Antibody-drug conjugates—an emerging class of cancer treatment

  • British Journal of Cancer
  • 2016
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

The origin of pegnology

FF Davis
  • Adv Drug Deliv Rev
  • 2002
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Polymer therapeutics: Top 10 selling pharmaceuticals - what next?

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2014
VIEW 5 EXCERPTS

Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

  • Integrative biology : quantitative biosciences from nano to macro
  • 2013
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL